Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

1. IFN-β therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses.PloS one · 2025
   Article
2. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.Neurology and therapy · 2024
   Review
3. SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis.Cureus · 2023
   Review
4. Breaking down the cellular responses to type I interferon neurotoxicity in the brain.Frontiers in immunology · 2023
   Review
5. ELAVL1 primarily couples mRNA stability with the 3' UTRs of interferon-stimulated genes.Cell reports · 2021
   Article
6. Mechanism of Nucleic Acid Sensing in Retinal Pigment Epithelium (RPE): RIG-I Mediates Type I Interferon Response in Human RPE.Journal of immunology research · 2021
   Article
7. RIG-I and TLR4 responses and adverse outcomes in pediatric influenza-related critical illness.The Journal of allergy and clinical immunology · 2020
   Observational
8. Type-I interferons in atherosclerosis.The Journal of experimental medicine · 2020
   Review
9. Proteomic changes during experimental de- and remyelination in the corpus callosum.PloS one · 2020
   Article
10. Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection.EBioMedicine · 2019
    Article
11. Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study.Journal of neurology · 2019
    Observational
12. Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis.International journal of molecular sciences · 2019
    Article
13. Host-Intrinsic Interferon Status in Infection and Immunity.Trends in molecular medicine · 2018
    Review
14. Cellular FLIP long isoform (cFLIPThe Journal of biological chemistry · 2018
    Article
15. CpG Type A Induction of an Early Protective Environment in Experimental Multiple Sclerosis.Mediators of inflammation · 2017
    Article
16. IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity.Journal of autoimmunity · 2016
    Article
17. T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases.Immunology and cell biology · 2016
    Review
18. pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation.Journal of autoimmunity · 2016
    Article
19. The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.Gene · 2016
    Review
20. CD13 restricts TLR4 endocytic signal transduction in inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2015
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as